Defining the toxicology of aging

Trends in Molecular Medicine

Volumn 20, Issue 7, 2014, Pages 375-384

  Sorrentino, Jessica A ^a,b   Sanoff, Hanna K ^b   Sharpless, Norman E ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; CDKN2a; Gerontogen; Senescence; Toxicology

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC; BENZENE DERIVATIVE; BIOLOGICAL MARKER; CARCINOGEN; CIGARETTE SMOKE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOTOXIC AGENT; POLLUTANT;

AGING; DIET; EXERCISE; HUMAN; IONIZING RADIATION; MAMMAL; NONHUMAN; OBESITY; PHENOTYPE; REVIEW; SENESCENCE; ULTRAVIOLET RADIATION; ANIMAL; CELL AGING; DRUG EFFECTS; PATHOLOGY; PHYSIOLOGY; POLLUTANT;

MAMMALIA;

AGING; ANIMALS; CELL AGING; ENVIRONMENTAL POLLUTANTS; HUMANS; PHENOTYPE;

EID: 84903543600     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.04.004     Document Type: Review

References (121)

1. Dillin A., et al. Timing requirements for insulin/IGF-1 signaling in C. elegans. Science 2002, 298:830-834.
2. Tatar M., et al. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science 2001, 292:107-110.
3. Vevea J.D., et al. Inheritance of the fittest mitochondria in yeast. Trends Cell Biol. 2014, 24:53-60.
4. Jin C., et al. Histone demethylase UTX-1 regulates C. elegans life span by targeting the insulin/IGF-1 signaling pathway. Cell Metab. 2011, 14:161-172.
5. Longo V.D., et al. Replicative and chronological aging in Saccharomyces cerevisiae. Cell Metab. 2012, 16:18-31.
6. Liang H., et al. Genetic mouse models of extended lifespan. Exp. Gerontol. 2003, 38:1353-1364.
7. Jeck W.R., et al. Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell 2012, 11:727-731.
8. Lunetta K.L., et al. Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. BMC Med. Genet. 2007, 8(Suppl. 1):S13.
9. Anisimov V.N., et al. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY) 2010, 2:945-958.
10. Harrison D.E., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
11. Butlin H.T. Three lectures on cancer of the scrotum in chimney-sweeps and others: delivered at the Royal College of Surgeons of England. Br. Med. J. 1892, 2:66-71.
12. Doll R., Hill A.B. Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. Br. Med. J. 1956, 2:1071-1081.
13. Perls T., Puca A. The genetics of aging-implications for pharmacogenomics. Pharmacogenomics 2002, 3:469-484.
14. Martin G.M. Interactions of aging and environmental agents: the gerontological perspective. Prog. Clin. Biol. Res. 1987, 228:25-80.
15. Kirkwood T.B. Understanding the odd science of aging. Cell 2005, 120:437-447.
16. Hoeijmakers J.H. DNA damage, aging, and cancer. N. Engl. J. Med. 2009, 361:1475-1485.
17. Long G.G., et al. Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation. Toxicol. Pathol. 2010, 38:43-50.
18. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522.
19. Herbig U., et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 2004, 14:501-513.
20. Allsopp R.C., et al. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10114-10118.
21. Serrano M., et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
22. Zhu J., et al. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 1998, 12:2997-3007.
23. Meng A., et al. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res. 2003, 63:5414-5419.
24. Bartkova J., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
25. Chen H., et al. Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev. 2009, 23:975-985.
26. Kim W.Y., Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275.
27. Bracken A.P., et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007, 21:525-530.
28. Dai C.Y., Enders G.H. p16 INK4a can initiate an autonomous senescence program. Oncogene 2000, 19:1613-1622.
29. Burd C.E., et al. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 2013, 152:340-351.
30. Wei W., et al. Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts. EMBO Rep. 2003, 4:1061-1066.
31. Krishnamurthy J., et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 2004, 114:1299-1307.
32. Liu Y., et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell 2009, 8:439-448.
33. Zindy F., et al. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997, 15:203-211.
34. Sorrentino J.A., et al. p16INK4a reporter mice reveal age-promoting effects of environmental toxicants. J. Clin. Invest. 2014, 124:169-173.
35. Molofsky A.V., et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006, 443:448-452.
36. Janzen V., et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 2006, 443:421-426.
37. Signer R.A., et al. Aging and cancer resistance in lymphoid progenitors are linked processes conferred by p16Ink4a and Arf. Genes Dev. 2008, 22:3115-3120.
38. Sousa-Victor P., et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 2014, 506:316-321.
39. Krishnamurthy J., et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006, 443:453-457.
40. Berent-Maoz B., et al. Fibroblast growth factor-7 partially reverses murine thymocyte progenitor aging by repression of Ink4a. Blood 2012, 119:5715-5721.
41. Chen H., et al. PDGF signalling controls age-dependent proliferation in pancreatic beta-cells. Nature 2011, 478:349-355.
42. Baker D.J., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479:232-236.
43. Sharpless N.E., DePinho R.A. How stem cells age and why this makes us grow old. Nat. Rev. Mol. Cell Biol. 2007, 8:703-713.
44. Davalos A.R., et al. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010, 29:273-283.
45. Lesne S., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
46. Kawarabayashi T., et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
47. Carroll K.K., et al. Dolichol: function, metabolism, and accumulation in human tissues. Biochem. Cell Biol. 1992, 70:382-384.
48. Marino M., et al. Accumulation of dolichol and impaired signal transduction in aging. Aging (Milano) 1997, 9:433-434.
49. Dimri G.P., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:9363-9367.
50. Tchkonia T., et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 2013, 123:966-972.
51. Sanoff H., et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J. Natl. Cancer Inst. 2014, 10.1093/jnci/dju057.
52. Herbig U., et al. Cellular senescence in aging primates. Science 2006, 311:1257.
53. Chen W., et al. Longitudinal versus cross-sectional evaluations of leukocyte telomere length dynamics: age-dependent telomere shortening is the rule. J. Gerontol. A: Biol. Sci. Med. Sci. 2011, 66:312-319.
54. Lin J., et al. Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. J. Immunol. Methods 2010, 352:71-80.
55. Longo D.L. Telomere dynamics in aging: much ado about nothing?. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64:963-964.
56. Van Ziffle J.A., et al. Telomere length in subpopulations of human hematopoietic cells. Stem Cells 2003, 21:654-660.
57. Allsopp R.C., et al. Effect of TERT over-expression on the long-term transplantation capacity of hematopoietic stem cells. Nat. Med. 2003, 9:369-371.
58. Valdes A.M., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005, 366:662-664.
59. Muezzinler A., et al. A systematic review of leukocyte telomere length and age in adults. Ageing Res. Rev. 2013, 12:509-519.
60. Melk A., et al. Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening. Kidney Int. 2003, 63:2134-2143.
61. Melk A., et al. Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney Int. 2004, 65:510-520.
62. Ressler S., et al. p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell 2006, 5:379-389.
63. Waaijer M.E., et al. The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell 2012, 11:722-725.
64. Nelson J.A., et al. Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell 2012, 11:916-918.
65. Liu Y., et al. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS ONE 2009, 4:e5027.
66. Wilson V.L., Jones P.A. DNA methylation decreases in aging but not in immortal cells. Science 1983, 220:1055-1057.
67. Maegawa S., et al. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res. 2010, 20:332-340.
68. Romanov G.A., Vanyushin B.F. Methylation of reiterated sequences in mammalian DNAs. Effects of the tissue type, age, malignancy and hormonal induction. Biochim. Biophys. Acta 1981, 653:204-218.
69. Hannum G., et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell 2013, 49:359-367.
70. Bell J.T., et al. Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet. 2012, 8:e1002629.
71. Koch C.M., Wagner W. Epigenetic-aging-signature to determine age in different tissues. Aging (Albany NY) 2011, 3:1018-1027.
72. Garagnani P., et al. Methylation of ELOVL2 gene as a new epigenetic marker of age. Aging Cell 2012, 11:1132-1134.
73. Thompson R.F., et al. Tissue-specific dysregulation of DNA methylation in aging. Aging Cell 2010, 9:506-518.
74. Fraga M.F., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:10604-10609.
75. West J., et al. Distinctive topology of age-associated epigenetic drift in the human interactome. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:14138-14143.
76. McClay J.L., et al. A methylome-wide study of aging using massively parallel sequencing of the methyl-CpG-enriched genomic fraction from blood in over 700 subjects. Hum. Mol. Genet. 2013, 10.1093/hmg/ddt511.
77. Wahlestedt M., et al. An epigenetic component of hematopoietic stem cell aging amenable to reprogramming into a young state. Blood 2013, 121:4257-4264.
78. Kapaj S., et al. Human health effects from chronic arsenic poisoning-a review. J. Environ. Sci. Health A: Tox. Hazard. Subst. Environ. Eng. 2006, 41:2399-2428.
79. Migliore L., Coppede F. Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat. Res. 2009, 674:73-84.
80. Banerjee M., et al. DNA repair deficiency leads to susceptibility to develop arsenic-induced premalignant skin lesions. Int. J. Cancer 2008, 123:283-287.
81. Andrew A.S., et al. Arsenic exposure is associated with decreased DNA repair in vitro and in individuals exposed to drinking water arsenic. Environ. Health Perspect. 2006, 114:1193-1198.
82. Wallace L.A. Major sources of benzene exposure. Environ. Health Perspect. 1989, 82:165-169.
83. Smith M.T., et al. Benzene exposure and risk of non-Hodgkin lymphoma. Cancer Epidemiol. Biomarkers Prev. 2007, 16:385-391.
84. Hoxha M., et al. Association between leukocyte telomere shortening and exposure to traffic pollution: a cross-sectional study on traffic officers and indoor office workers. Environ. Health 2009, 8:41.
85. Zhang X., et al. Environmental and occupational exposure to chemicals and telomere length in human studies. Occup. Environ. Med. 2013, 70:743-749.
86. Kligman L.H. Photoaging. Manifestations, prevention, and treatment. Clin. Geriatr. Med. 1989, 5:235-251.
87. Scharffetter-Kochanek K., et al. Photoaging of the skin from phenotype to mechanisms. Exp. Gerontol. 2000, 35:307-316.
88. Setlow R.B., Carrier W.L. Pyrimidine dimers in ultraviolet-irradiated DNA's. J. Mol. Biol. 1966, 17:237-254.
89. Cole L.J., et al. Late effects of x-radiation. The influence of dose fractionation on life span, leukemia, and nephrosclerosis incidence in mice. Radiat. Res. 1960, 12:173-185.
90. Upton A.C. Ionizing radiation and the aging process; a review. J. Gerontol. 1957, 12:306-313.
91. Rodier F., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11:973-979.
92. Freund A., et al. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 2011, 30:1536-1548.
93. Lakin N.D., Jackson S.P. Regulation of p53 in response to DNA damage. Oncogene 1999, 18:7644-7655.
94. Marcoux S., et al. Expression of the senescence marker p16INK4a in skin biopsies of acute lymphoblastic leukemia survivors: a pilot study. Radiat. Oncol. 2013, 8:252.
95. Bernhard D., et al. Cigarette smoke-an aging accelerator?. Exp. Gerontol. 2007, 42:160-165.
96. Ito K., Barnes P.J. COPD as a disease of accelerated lung aging. Chest 2009, 135:173-180.
97. Grady D., Ernster V. Does cigarette smoking make you ugly and old?. Am. J. Epidemiol. 1992, 135:839-842.
98. DeMarini D.M. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat. Res. 2004, 567:447-474.
99. Pfeifer G.P., et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21:7435-7451.
100. Mirabello L., et al. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009, 8:405-413.
101. Song Z., et al. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell 2010, 9:607-615.
102. Huvenne W., et al. Different regulation of cigarette smoke induced inflammation in upper versus lower airways. Respir. Res. 2010, 11:100.
103. Ness K.K., et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the st jude lifetime cohort study. J. Clin. Oncol. 2013, 31:4496-4503.
104. Flegal K.M., et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007, 298:2028-2037.
105. Ogden C.L., et al. Prevalence of obesity among adults: United States, 2011-2012 2013, Centers for Disease Control and Prevention.
106. Calle E.E., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003, 348:1625-1638.
107. Flegal K.M., et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013, 309:71-82.
108. Nettleton J.A., et al. Dietary patterns, food groups, and telomere length in the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Clin. Nutr. 2008, 88:1405-1412.
109. Masoro E.J. Overview of caloric restriction and ageing. Mech. Ageing Dev. 2005, 126:913-922.
110. Flegal K.M., et al. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005, 293:1861-1867.
111. Cassidy A., et al. Associations between diet, lifestyle factors, and telomere length in women. Am. J. Clin. Nutr. 2010, 91:1273-1280.
112. Fried L.P., et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A: Biol. Sci. Med. Sci. 2001, 56:M146-M156.
113. Werner C., et al. Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Circulation 2009, 120:2438-2447.
114. LaRocca T.J., et al. Leukocyte telomere length is preserved with aging in endurance exercise-trained adults and related to maximal aerobic capacity. Mech. Ageing Dev. 2010, 131:165-167.
115. Simpson R.J., et al. Senescent phenotypes and telomere lengths of peripheral blood T-cells mobilized by acute exercise in humans. Exerc. Immunol. Rev. 2010, 16:40-55.
116. Ludlow A.T., et al. Relationship between physical activity level, telomere length, and telomerase activity. Med. Sci. Sports Exerc. 2008, 40:1764-1771.
117. Drela N., et al. Moderate exercise may attenuate some aspects of immunosenescence. BMC Geriatr. 2004, 4:8.
118. McEwen B.S. Protective and damaging effects of stress mediators. N. Engl. J. Med. 1998, 338:171-179.
119. Liu J., Mori A. Stress, aging, and brain oxidative damage. Neurochem. Res. 1999, 24:1479-1497.
120. Miller G.E., et al. Psychological stress in childhood and susceptibility to the chronic diseases of aging: moving toward a model of behavioral and biological mechanisms. Psychol. Bull. 2011, 137:959-997.
121. Epel E.S., et al. Accelerated telomere shortening in response to life stress. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17312-17315.